PL374221A1

Antibody inhibitors of gdf-8 and uses thereof

Abstract

The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing or treating degenerative disorders of muscle, bone, or insulin metabolism.

Term

Term ended

Projected expiry passed 26 September 2022, 4 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

31 members in 13 offices

This recordMember, by publication datePriority claim3 more offices are in the list below

Priority claims3

Priority claims
DocumentOfficeKindDate
32452801United States of AmericaP
0160324528
US20010324528P

Members31

Family members, oldest first
DocumentOfficeKind
CA2469230A1CanadaA1
WO03027248A2World Intellectual Property Organization (WIPO)A2
WO03027248A3World Intellectual Property Organization (WIPO)A3
US2003138422A1United States of AmericaA1
NO20041582LNorwayL
WO03027248A8World Intellectual Property Organization (WIPO)A8
EP1438068A2European Patent Office (EPO)A2
JP2005510212AJapanA
MXPA04002834AMexicoA
PL374221A1This recordPolandA1
EP1438068A4European Patent Office (EPO)A4
BR0212809ABrazilA
NZ532034ANew ZealandA
ZA200402265BSouth AfricaB
US7320789B2United States of AmericaB2
AU2002347773B2AustraliaB2
ZA200606082BSouth AfricaB
JP2009067798AJapanA
JP4452077B2JapanB2
US7731961B1United States of AmericaB1
US2011020330A1United States of AmericaA1
EP2316851A1European Patent Office (EPO)A1
US8092798B2United States of AmericaB2
US2012107928A1United States of AmericaA1
US8710202B2United States of AmericaB2
EP1438068B1European Patent Office (EPO)B1
PT1438068EPortugalE
US2015024484A1United States of AmericaA1
NO336528B1NorwayB1
US9505831B2United States of AmericaB2
CA2469230CCanadaC